Company profile
ABEONA THERAPEUTICS INC.
NASDAQ:ABEOBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZEVASKYN | approved | $11.4MQ2 2026 | 1 | approved |
| PEXIGANAN ACETATE | phase3 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05725018 | phase3 | active_not_recruiting | 2023-04-02 | 2025-09-30 | Abeona Therapeutics, Inc | A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients |
| NCT00385502 | phase2 | completed | 2006-09-01 | 2008-06-01 | Abeona Therapeutics, Inc | A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail |
| NCT03315182 | phase1_2 | terminated | 2017-10-16 | 2022-04-07 | Abeona Therapeutics, Inc | Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB |
| NCT01263379 | phase1_2 | completed | 2010-10-05 | 2022-03-09 | Abeona Therapeutics, Inc | Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa |
| NCT00563433 | phase3 | completed | 1994-08-01 | 1996-07-01 | Abeona Therapeutics, Inc | MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125807 | 2025-04-28 | BLA | ABEONA THERAPEUTICS INC. | |||||
Loading… | ||||||||